Point72 Europe London LLP Purchases Shares of 77,200 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Point72 Europe London LLP purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 77,200 shares of the medical equipment provider's stock, valued at approximately $6,198,000. Point72 Europe London LLP owned about 0.11% of Lantheus at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. UMB Bank n.a. increased its position in Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 247 shares during the period. GAMMA Investing LLC raised its position in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares in the last quarter. Principal Securities Inc. purchased a new position in Lantheus in the fourth quarter worth $28,000. Fidelis Capital Partners LLC acquired a new stake in Lantheus in the first quarter valued at $34,000. Finally, FinTrust Capital Advisors LLC boosted its position in shares of Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 232 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LNTH shares. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. JMP Securities dropped their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Leerink Partners boosted their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Finally, B. Riley boosted their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Insider Buying and Selling

In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the business's stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the transaction, the director now directly owns 11,978 shares in the company, valued at approximately $1,138,389.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares in the company, valued at approximately $1,138,389.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is owned by insiders.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $3.81 during trading on Wednesday, reaching $107.95. The company had a trading volume of 673,017 shares, compared to its average volume of 1,013,960. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $7.49 billion, a PE ratio of 17.06 and a beta of 0.50. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The stock has a 50-day moving average price of $105.14 and a two-hundred day moving average price of $85.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 EPS. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.